Background
==========

Post-transplant lymphoproliferative disorder (PTLD) is a rare complication following solid organ transplantation and allogeneic hematopoietic stem cell transplantation (Allo-HSCT), which gives rise to high mortality rates \[[@b1-anntransplant-24-175],[@b2-anntransplant-24-175]\]. PTLDs are a heterogeneous group of diseases \[[@b3-anntransplant-24-175]\]. According to the 2016 World Health Organization (WHO) lymphoma classification, PTLDs are divided into infectious mononucleosis PTLD, plasmacytic hyperplasia PTLD, classical Hodgkin lymphoma PTLD, florid follicular hyperplasia PTLD, monomorphic PTLD, and polymorphic PTLD \[[@b4-anntransplant-24-175]\].

It has been reported that many risk factors, such as HLA mismatch, T-cell depletion of donor grafts, and use of antithymocyte globulin, can increase the incidence of PTLD \[[@b5-anntransplant-24-175],[@b6-anntransplant-24-175]\]. The pathogenesis for PTLD is assumed to be linked with impairment of cellular immunity and EBV reactivation \[[@b7-anntransplant-24-175],[@b8-anntransplant-24-175]\]. A clinical symptom of PTLD is fever alone or with lymphadenopathy, which is frequently accompanied by extra nodal sites \[[@b9-anntransplant-24-175],[@b10-anntransplant-24-175]\].

The treatment of PTLD varies depending on the classification and site of the disease, ranging from reducing immunosuppression to administration of rituximab alone or with chemotherapy or radiotherapy. Treatment can also be comprised of a combination of all of these approaches. Rituximab has been efficacious to the treatment of CD20 positive PTLD \[[@b11-anntransplant-24-175]--[@b13-anntransplant-24-175]\].

The purpose of this analysis was to investigate responses and prognostic factors of rituximab-based treatment.

Material and Methods
====================

This was a single-center retrospective analysis based on 27 patients who were diagnosed with PTLD following Allo-HSCT between January 1, 2007 and June 1, 2018 at the Chinese PLA General Hospital. The analysis included the following clinical characteristics for each patient: age, diagnosis, gender, conditioning regimens, EBV and cytomegalovirus (CMV) reactivation, and grade of graft-versus-host disease (GVHD). Written informed consent was obtained from each patient. Patients who participated in this study were approved by the Chinese PLA General Hospital ethical committee.

Conditioning regimen
--------------------

The conditioning regimens were as follows: 1) Bu/Cy-conditioning regimen consisted of busulfan (3.2 mg/kg/day for 3 days) together with cyclophosphamide (60 mg/kg for 2 days), 2) FC-conditioning regimen consisted of fludarabine (30 mg/m^2^ for 5 days) together with cyclophosphamide (50 mg/m^2^ for 4 days), and 3) FB-conditioning regimen consisted of fludarabine (30 mg/m^2^/day for 4 days) with busulfan (3.2 mg/kg/day IV for 3 days). The conditioning regimen for all 27 patients also included 2.5 mg/kg/day thymoglobulin (Sangstat, Lyon, France) for 4 days.

Infection and GVHD prophylaxis
------------------------------

From the first day of conditioning, all patients received antiviral prophylaxis with acyclovir, as well as pneumocystis prophylaxis with cotrimoxazole. No systematic antibacterial prophylaxis was given before stem cell engraftment.

Acute and chronic GVHD were evaluated according to the Seattle standard criteria. Prophylaxis against GVHD consisted of 0.5 g mycophenolate mofetil every 12 hours starting on day 1 for 28 days, followed by cyclosporine starting on day 6, and a short course of methotrexate (15 mg/m^2^ on day +1; 10 mg/m^2^ on days +3, +6, and +11). Grades II to IV acute GVHD were usually treated with methylprednisolone 1--2 mg/kg/day. Extensive chronic GVHD was treated with prednisone 1 mg/kg/day.

EBV-reactivation
----------------

Quantitative PCR for detection of EBV copies of plasma, was performed as described elsewhere \[[@b14-anntransplant-24-175]\], the results were expressed as viral copy number per mL. EBV DNA load was monitored at least once a week during the first 4 or more months after transplantation, until EBV DNA became undetectable \[[@b15-anntransplant-24-175]\].

Diagnosis and treatment of PTLD
-------------------------------

PTLD diagnosis was based on histopathology obtained by biopsy. Routinely, diagnostic tissue samples were examined independently by 2 pathologists with agreement on the diagnoses and subtype according to the 2016 WHO lymphoma classification. In order to detect lymphoproliferative sites, all patients diagnosed with PTLD underwent blood tests, and computed tomography (CT) scans. PTLD can be diagnosed as either probable or proven. The following criteria lead to a probable PTLD diagnosis: significant lymphadenopathy, hepatosplenomegaly, or other organ manifestations (without tissue biopsy, but in the absence of other documented cause). Conversely, a proven PTLD diagnosis is defined as a histologically diagnosed PTLD.

Patients accepted 4 weekly doses of rituximab (375 mg/m^2^), alone or combined with 1 to 4 courses of standard CHOP chemotherapy (cyclophosphamide 750 mg/m^2^ on day 1, doxorubicin 50 mg/m^2^ on day 1, vincristine 1.4 mg/m^2^ on day 1, prednisone 50 mg/m^2^ on day 1 to day 5) or COP therapy (cyclophosphamide 750 mg/m^2^ on day 1, prednisone 50 mg/m^2^ on day 1 to day 5).

Definitions
-----------

Overall survival (OS) was calculated from the onset of transplantation to the date of the latest follow-up or to the date of death. Response criteria are defined according to the International Harmonization Project on Lymphoma \[[@b16-anntransplant-24-175]\]. Safety data were evaluated using the NCICTCAE criteria version 3.0. The virologic response was also assessed based on EBV DNA copies reduction.

Statistical analysis
--------------------

Descriptive statistics were used to report the 27 patients' general characteristics. Percentages were reported for categorical variables, whereas medians and ranges were reported for continuous variables. The prognostic factors of PTLD were treated with rituximab and were evaluated as a time-dependent variable in a Cox proportional-hazards regression model. The probabilities of OS were estimated by the Kaplan-Meier survival method.

The impact of the following variables was analyzed: age at transplant (≥50 versus \<50 years), gender (female versus male), acute GVHD at the time of PTLD diagnosis (\>grade II versus grade I--II, chronic or absent), time from transplant to PTLD diagnosis (≥100 days versus \<100 days), maximum EBV viral load (≥10^6^ versus \<10^6^ copies/mL), EBV reactivation turned negative after 2 doses of rituximab (no versus yes), bacterial or fungal infection (with versus without), Eastern Cooperative Oncology Group (ECOG) score standard (3--4 versus 0--2) and LDH level (high *vs.* normal). Multivariable analysis included only candidate variables which were statistically significant at a *P*\<0.15 level from univariate analysis \[[@b16-anntransplant-24-175]\]. The level of significance in all cases was set at *P*\<0.05. Statistical tests were run on SPSS (version 18.0). Kaplan-Meier survival-curve analyses were performed using Prism 6.0 software (GraphPad Software).

Results
=======

Patient characteristics
-----------------------

Patient characteristics are presented in [Table 1](#t1-anntransplant-24-175){ref-type="table"}. Twenty-seven cases of PTLD were identified, of which, 8 were females and 19 were males. The median age was 27 years old (range, 12--61 years old). Among all patients, 25 individuals had a mismatched family donor, whereas 2 individuals had matched unrelated donors. Primary diseases included acute lymphoblastic leukemia (n=9), acute myeloblastic leukemia (n=11), non-Hodgkin lymphoma (n=1), myelodysplastic syndrome (n=2), and severe aplastic anemia (n=4). Among the 27 patients, 1 patient developed platelets graft failure, whereas all patients developed a granulocyte graft successfully. The median time to neutrophil recovery was 11 days (range, 8--9 days), whereas the median time to platelet recovery was 15 days (range, 9--47 days). Clinically significant grade I--II acute GVHD occurred in 16 cases (59.26%), and grade III--IV acute GVHD occurred in 2 cases (7.41%). Extensive chronic GVHD was diagnosed in 1 case (3.70%), 24 cases (88.89%) had concomitant CMV infection, and 9 cases (33.33%) had hemorrhagic cystitis.

EBV-reactivation and PTLD
-------------------------

As [Table 2](#t2-anntransplant-24-175){ref-type="table"} shows, 27 cases had detectable EBV reactivation and the median of peak EBV DNA copies was 12.73×10^4^ per mL (range=8.346×10^3^--1.774×10^7^ per mL).

PTLD was proven by biopsy in 8 cases, whereas 19 cases had probable PTLD. The median time to PTLD onset was 58 days (range, 22--202 days) after transplantation. According to the WHO classification, pathologic findings varied in the following ways: 2 cases had polymorphic PTLD, 5 cases had diffuse large B-cell lymphoma, 1 case had Burkitt lymphoma, 19 patients had fever, and 21 patients had lymphadenopathy. Among 8 proven PTLD cases, CD20 status was positive in 100.0% of individuals. An extra nodal site was involved in 14.81% (n=4) of cases and the location of the extra nodal sites were as follows: gastrointestinal tract (n=2), central nervous system (n=1), and liver (n=1).

Outcome of treatments
---------------------

As [Table 2](#t2-anntransplant-24-175){ref-type="table"} shows, the following outcomes occurred at the end of the study: 22 of 27 patients cleared EBV after rituximab treatment, 20 of 27 patients had a complete response, 2 of 27 patients had a partial response, and 4 of 27 patients exhibited progressive disease. One patient responded well to rituximab -- combined with COP followed by 2 doses of rituximab treatment -- but died of fungal pneumonia. One patient was given an EBV-specific CTL lymphocyte infusion followed by rituximab treatment, but died of PTLD progression. Taken together, 14 of 27 patients were still alive at the end of study, 4 patients died from PTLD, 3 patients died from GVHD, 2 patients died from fungal pneumonia, and the remaining 4 patients died from relapse of the primary disease. [Figure 1](#f1-anntransplant-24-175){ref-type="fig"} shows OS analysis by the Kaplan-Meier survival method.

Side effects
------------

There were no obvious side effects from rituximab infusion, and tolerance was generally good.

Prognosis factors for PTLD
--------------------------

Univariate analysis revealed that lower OS was correlated with EBV was not negative after treatment with 1 or 2 doses of rituximab (*P*=0.007, HR=4.758,95%CI, 1.535--14.750), ECOG score standard ≥3--4 (*P*=0.002, HR=25.125, 95% CI, 3.190--197.884), EBV viral load ≥10^6^ copies/mL (*P*=0.033, HR=3.408, 95% CI, 1.103--10.530) and with bacterial or fungal infection (*P*=0.004, HR=9.234, 95% CI, 1.995--42.743) ([Table 3](#t3-anntransplant-24-175){ref-type="table"}). Multivariate analysis identified that EBV was not negative after treatment with 1 or 2 doses of rituximab (*P*=0.033, HR=4.273,95% CI,1.076--16.974), ECOG score standard ≥3--4 (*P*=0.002, HR=36.986, 95% CI, 3.775--362.345), and females (*P*=0.018, HR=5.688, 95% CI, 1.352--23.921) were independently associated with lower OS ([Table 4](#t4-anntransplant-24-175){ref-type="table"}). [Figure 2](#f2-anntransplant-24-175){ref-type="fig"} shows the Kaplan-Meier survival-method analysis of 5 significant prognostic factors.

Discussion
==========

PTLDs are dangerous and fatal complications after Allo-HSCTs. It has been reported that patients under 10 years of age, as well as patients over 60 years of age, are more likely to develop PTLDs \[[@b3-anntransplant-24-175],[@b17-anntransplant-24-175],[@b18-anntransplant-24-175]\]. "Early" PTLD occurs within the first year of transplantation and "late" PTLD occurs beyond the first year \[[@b11-anntransplant-24-175],[@b19-anntransplant-24-175]\]. It has been reported that "early" PTLD may have a causative association with EBV reactivation \[[@b20-anntransplant-24-175],[@b21-anntransplant-24-175]\]. In the present study, all patients had "early" PTLD and detectable EBV reactivation. Mortality of PTLD can be high, but varies among medical centers and also depends on the type of transplantation \[[@b22-anntransplant-24-175]\]. In the present study, 13 of 27 patients died, and the mortality rate was 48.15%.

The key of early diagnosis of PTLD is active awareness. When a patient exhibits adenopathy and fever after Allo-HSCT, a diagnosis of PTLD should be considered. To clarify the diagnoses, tissue biopsy is required. In addition, it is recommended that early diagnosis of PTLD be achieved through the monitoring of EBV DNA copies before onset of clinical symptoms.

Intense immunosuppression is one of the most common factors that stimulates PTLD in transplanted patients \[[@b17-anntransplant-24-175],[@b23-anntransplant-24-175]\]. Strikingly, 55--65% of PTLDs are associated with EBV reactivation \[[@b24-anntransplant-24-175],[@b25-anntransplant-24-175]\]. Immune control of EBV reactivation is mediated by T cell responses, but when patients are undergoing Allo-HSCT, the use of immunosuppression against GVHD leads to a profound deficit in cell response. This, in turn, leads to increased viral replication and to an accumulation of infected B-cells \[[@b26-anntransplant-24-175],[@b27-anntransplant-24-175]\]. In the present study, EBV reactivation was detected in 29 of 29 patients (100%)

Current guidelines recommend that rituximab, reduction of immunosuppression, and EBV-specific cytotoxic-T-cell therapy are the first-line of therapies, while donor lymphocyte infusions (DLI) or chemotherapy are the second-line of therapies \[[@b15-anntransplant-24-175]\]. However, the response rates of reductions of immunosuppressive drugs are low \[[@b28-anntransplant-24-175]\]. Additionally, reduction of immunosuppression is known to be associated with a high risk of GVHD. EBV-specific cytotoxic-T-cell therapy is not available at most transplant centers. The remission rate of DLI is more than 70% for PTLD, but it can also increase the risk of GVHD \[[@b29-anntransplant-24-175]\]. Rituximab has become an available alternative therapy for PTLD, and may additionally reduce the risk of acute or chronic GVHD \[[@b30-anntransplant-24-175],[@b31-anntransplant-24-175]\]. CD20 is the target of rituximab, and many reports demonstrate that rituximab can inhibit B-cell proliferation \[[@b32-anntransplant-24-175],[@b33-anntransplant-24-175]\], which induces some patients to achieve long-term disease-free survival. In addition, rituximab-based treatment -- following failure of reduced immunosuppression -- is an alternative therapy of PTLD \[[@b34-anntransplant-24-175]\]. In this analysis, 20 of 27 patients had a complete response, whereas 2 of 27 patients had a partial response. One patient was diagnosed with central nervous system PTLD, for which there is no standard therapy, although possible therapeutic options include rituximab alone or combined with chemotherapy through either intravenous \[[@b35-anntransplant-24-175]\] or intrathecal injections \[[@b36-anntransplant-24-175]\]. After treatment with intravenous injection of rituximab alone, clinical symptoms of nausea and vomiting disappeared and cerebrospinal fluid EBV is negative. In summary, the therapeutic effect in the present study suggests that rituximab is an efficacious choice for PTLD patients. There were no obvious side effects, and tolerance of rituximab infusion was generally good. Additionally, there was no hematological toxicity and no patients experienced graft rejection.

In the era of PTLD treatments becoming rituximab-based, it is necessary to obtain detailed knowledge about prognostic factors. Poor PTLD prognosis is associated with poor performance status, CNS disease, late onset of disease, advanced age, disease involving multiple sites, and elevated LDH \[[@b37-anntransplant-24-175],[@b38-anntransplant-24-175]\]. Additionally, the initial response to rituximab is regarded as a reliable prognostic factor for PTLD \[[@b39-anntransplant-24-175]\]. In this study, the initial responses of 10 patients to rituximab were positive and all were still alive. Univariate analysis revealed that lower OS was correlated with EBV was not negative after treatment with 1 or 2 dose of rituximab, ECOG score standard ≥3--4, EBV DNA load ≥10^6^ copies/ml and with bacterial or fungal infection. Multivariate analysis identified that EBV was not negative after treatment with 1 or 2 doses of rituximab, ECOG score standard ≥3--4 and females were independently associated with lower OS.

Several concerns have been raised \[[@b40-anntransplant-24-175]\], including the fact that rituximab cannot restore immunity to EBV reactivation. Administration of rituximab to individuals who develop EBV copies exceed a threshold associated with PTLD, and it has led to an obvious reduction in mortality \[[@b41-anntransplant-24-175],[@b42-anntransplant-24-175]\].

The major limitations of the present study were its small sample size and the short follow-up time. Despite these drawbacks, we identified that a rituximab**-**based treatment is a safe and effective strategy for patients who were diagnosed as PTLD. Further studies with more patients from multi-centers will be required.

Conclusions
===========

The diagnosis of PTLD can be established on a proven or probable level. Rituximab**-**based treatment is a safe and effective strategy for patients who are diagnosed with PTLD following Allo-HSCT. Identified prognostic factors may help to identify patients who have a higher risk of mortality.

**Source of support:** Departmental sources
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###### 

Patient and transplantation characteristics of my study population.

  Characteristics                                          N                         \%
  -------------------------------------------------------- ------------------------- -------
  Patient age, median (range)                              27 (12--61) years         
  Patient gender                                                                     
   Male                                                    19                        70.37
   Female                                                  8                         29.63
  Diagnosis                                                                          
   AA                                                      4                         14.82
   ALL                                                     9                         33.33
   AML                                                     11                        40.74
   MDS                                                     2                         7.41
   NHL                                                     1                         3.70
  Conditioning regimen                                                               
   With ATG                                                27                        100
   Without ATG                                             0                         0
  Source of stem cell                                                                
   PB                                                      27                        100
   BM                                                      0                         0
  Donor                                                                              
   Sibling                                                 25                        92.59
   MUD                                                     2                         7.41
  ABO compatibility                                                                  
   Yes                                                     14                        51.85
   No                                                      13                        48.15
  Hemorrhagic cystitis                                                               
   Yes                                                     9                         33.33
   No                                                      18                        66.67
  EBV reactivation                                                                   
   Positive                                                27                        100
   Negative                                                0                         0
  CMV reactivation                                                                   
   Positive                                                24                        88.89
   Negative                                                3                         11.11
  GVHD                                                                               
   Without GVHD                                            8                         29.63
   Acute I--II GVHD                                        16                        59.26
   Acute III--IV GVHD                                      2                         7.41
   Chronic GVHD                                            1                         3.70
  Use basiliximab                                                                    
   Yes                                                     3                         11.11
   No                                                      24                        88.89
  Times of transplantation                                                           
   \>One time                                              2                         7.41
   One time                                                25                        92.59
  Condition regimen                                                                  
   FB                                                      7                         25.93
   FC                                                      2                         7.41
   Bu/Cy                                                   18                        66.66
  Status at transplantation                                                          
   CR                                                      15                        55.56
   NR                                                      8                         29.63
   Untreated                                               4                         14.81
   PTLD classification                                                               
   Probable PTLD                                           19                        70.37
   Proven PTLD                                             8                         27.59
  PTLD onset time                                                                    
   \<100 days post SCT                                     24                        88.89
   ≥100 days post SCT                                      3                         11.11
  MNC median (range) ×10^8^/kg                             8.75 (4.81--23.12)        
  CD34+ cell count median (range) ×10^6^/kg                3.75 (0.93--10.87)        
  Neutrophil recovery(days) \>0.5×10^9^/l median (range)   11 (8--9)                 
  Platelets recovery(days) \>0.5×10^9^/l median (range)    15 (9--47)                
  Median day of PTLD diagnosis (range)                     58 (22--202)              
  Median maximum EBV copies/ml (range)                     127300 (8346--17740000)   

PTLD -- post-transplant lymphoproliferative disorder; AA -- aplastic anemia; ALL -- acute lymphoblastic leukemia; AML -- acute myeloblastic leukemia; MDS -- myelodysplastic syndrome; NHL -- non-Hodgkin lymphoma; ATG -- antithymoglobulins; PB -- peripheral blood; BM -- bone marrow; MUD -- matched unrelated donor; CMV -- cytomegalovirus; EBV -- Epstein-Barr Virus; GVHD -- graft-*vs.*-host disease; Bu -- busulfan; Cy -- cyclophosphamide; FB -- fludarabine+busulfan; Ara-C -- cytarabine; FC -- fludarabine+cyclophosphamide; MNC -- mononuclear cells count; CR -- complete remission; NR -- none remission.

###### 

Characteristics of 27 patients of PTLD.

  No   Age   Gender   Diagnosis   Regimen   PTLD classification   Symptom                      Treatment   Peak EBV DNAemia, copies/ml   Histology            Outcome, cause of death
  ---- ----- -------- ----------- --------- --------------------- ---------------------------- ----------- ----------------------------- -------------------- -------------------------
  1    43    Male     AML         FB        Proven                Fever, lymphadenopathy       Rx5         130000                        Bunkitt's lymphoma   Dead GVHD
  2    15    Male     AA          Bu/Cy     Probable              Fever, lymphadenopathy       Rx4         127300                        --                   Alive
  3    15    Male     AML         FB        Proven                Fever, lymphadenopathy       Rx4         5114000                       DLBCL                Dead PTLD
  4    16    Male     ALL         Bu/Cy     Probable              Fever, lymphadenopathy       Rx4         49510                         --                   Alive
  5    19    Female   AML         Bu/Cy     Probable              Lymphadenopathy              Rx3         362500                        --                   Alive
  6    19    Male     AA          Bu/Cy     Probable              Fever, lymphadenopathy       Rx4         3850000                       --                   Alive
  7    22    Male     AML         Bu/Cy     Probable              lymphadenopathy              Rx3         10440                         --                   Alive
  8    22    Female   ALL         Bu/Cy     Probable              Fever, lymphadenopathy       Rx3         4362000                       --                   Dead GVHD
  9    27    Female   ALL         Bu/Cy     Probable              Fever, lymphadenopathy       Rx3         42810                         --                   Alive
  10   35    Male     ALL         Bu/Cy     Probable              Fever                        Rx2         62700                         --                   Dead GVHD
  11   40    Female   ALL         FB        Proven                Lymphadenopathy              Rx3+COPx1   8346                          DLBCL                Dead fungal pneumonia
  12   42    Male     ALL         Bu/Cy     Probable              Lymphadenopathy              Rx3         64450                         --                   Alive
  13   51    Male     AML         FB        Probable              Fever, lymphadenopathy       Rx4         1571000                       --                   Dead fungal pneumonia
  14   56    Male     AML         FB        Proven                Fever, lymphadenopathy       Rx3         1465000                       Polymorphic          Alive
  15   61    Male     AML         FB        Probable              Fever, lymphadenopathy       Rx1         236000                        --                   Dead AML
  16   12    Male     AML         FB        Proven                Fever, lymphadenopathy       Rx4         35100                         DLBCL                Alive
  17   35    Female   MDS         Bu/Cy     Probable              Fever, lymphadenopathy       Rx2         34560                         --                   Dead MDS
  18   31    Male     NHL         Bu/Cy     Probable              Lymphadenopathy              Rx4+CTL     12260000                      --                   Dead PTLD
  19   24    Male     AA          FC        Probable              Fever, lymphadenopathy       Rx2         17740000                      --                   Dead PTLD
  20   32    Male     ALL         Bu/Cy     Probable              Fever, lymphadenopathy       Rx1         604900                        --                   Dead ALL
  21   26    Female   MDS         Bu/Cy     Proven                Fever, lymphadenopathy       Rx3         478800                        Polymorphic          Dead PTLD
  22   35    Female   AML         Bu/Cy     Probable              Diarrhea, lymphadenopathy    Rx4         92650                         --                   Alive
  23   27    Male     AML         Bu/Cy     Probable              Nausea, vomiting             Rx4         236600                        --                   Alive
  24   33    Male     ALL         Bu/Cy     Probable              Fever, hepatic dysfunction   Rx2         15520                         --                   Alive
  25   35    Female   AML         Bu/Cy     Probable              Diarrhea                     Rx4         19470                         --                   Dead AML
  26   19    Male     ALL         Bu/Cy     Proven                Fever                        Rx4         20790                         DLBCL                Alive
  27   21    Male     AA          FC        Proven                Fever                        Rx4         49700                         DLBCL                Alive

AA -- aplastic anemia; ALL -- acute lymphoblastic leukemia; AML -- acute myeloblastic leukemia; MDS -- myelodysplastic syndrome; NHL -- non-Hodgkin lymphoma; ATG -- antithymoglobulins; EBV -- Epstein-Barr Virus; Bu -- busulfan; Cy -- cyclophosphamide; FB -- fludarabine+busulfan; FC -- fludarabine+cyclophosphamide; R -- rituximab; RI -- reduction of immunosuppression; DLBCL -- diffuse large B cell lymphoma; CTL -- cytotoxic lymphocyte; COP -- cyclophosphamide+vincristine+prednisone.

###### 

Univariate Cox proportional hazards regression techniques analyses for overall survival of PTLD.

  Factor                                      P       OR       95%CI
  ------------------------------------------- ------- -------- ----------------
  Gender                                      0.110   2.448    0.817--7.336
   Female                                                      
   Male                                                        
  Age                                         0.272   2.350    0.511--10.806
   ≥50 years                                                   
   \<50 years                                                  
  PTLD disease                                0.442   0.550    0.120--2.525
   \<100 days post HSCT                                        
   ≥100 days post HSCT                                         
  EBV negative after two doses of rituximab   0.007   4.758    1.535--14.750
   No                                                          
   Yes                                                         
  Acute GVHD III-IV                           0.616   1.352    0.415--4.401
   Yes                                                         
   No                                                          
  Infection (bacteria or fungi)               0.004   9.234    1.995--42.743
   Yes                                                         
   No                                                          
  ECOG score standard                         0.002   25.125   3.190--197.884
   3--4                                                        
   0--2                                                        
  LDH                                         0.754   1.387    0.179--10.771
   ≥250 U/L                                                    
   \<250 U/L                                                   
  EBV viral load ≥10^6^ copies/ml             0.033   3.408    1.103--10.530
   Yes                                                         
   No                                                          

LDH -- lactate dehydrogena.

###### 

Multivariate Cox proportional hazards regression techniques analyses for overall survival of PTLD.

  Factor                                      P       OR       95%CI
  ------------------------------------------- ------- -------- ----------------
  Gender                                      0.018   5.688    1.352--23.921
   Female                                                      
   Male                                                        
  EBV negative after two doses of rituximab   0.039   4.273    1.076--16.974
   No                                                          
   Yes                                                         
  Infection (bacteria or fungi)               0.254   2.726    0.486--15.285
   Yes                                                         
   No                                                          
  ECOG score standard                         0.002   36.986   3.775--362.345
   3--4                                                        
   0--2                                                        
  EBV viral load ≥10^6^ copies/ml             0.493   2.035    0.267--15.502
   Yes                                                         
   No                                                          

PTLD -- post-transplant lymphoproliferative disorder; GVHD -- graft-*vs.*-host disease.
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